Esperion Therapeutics ESPR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's EBITDA?
- Esperion Therapeutics (ESPR) reported EBITDA of -$6.55M in Q1 2026.
- How has Esperion Therapeutics's EBITDA changed year-over-year?
- Esperion Therapeutics's EBITDA increased by 70.3% year-over-year, from -$22.07M to -$6.55M.
- What is the long-term trend for Esperion Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Esperion Therapeutics's EBITDA has grown at a -28.1% compound annual growth rate (CAGR), from -$226.12M to $60.38M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.